about
Drug-induced renal damage in preterm neonates: state of the art and methods for early detectionEducational paper: do we need neonatal clinical pharmacologists?Neonatal drug therapy: The first frontier of therapeutics for childrenPhysiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation.Neonatal pain management: still in search for the Holy GrailLimited predictability of amikacin clearance in extreme premature neonates at birthImpact of ibuprofen administration on renal drug clearance in the first weeks of lifePhysiology-based IVIVE predictions of tramadol from in vitro metabolism data.Development of a Physiologically-Based Pharmacokinetic Model for Preterm Neonates: Evaluation with In Vivo Data.Tympanic, infrared skin, and temporal artery scan thermometers compared with rectal measurement in children: a real-life assessmentProspective validation of neonatal vancomycin dosing regimens is urgently needed.Clinical pharmacology in neonates: small size, huge variabilityThe EPIBEL study: outcomes to discharge from hospital for extremely preterm infants in Belgium.Educational paper: Retinopathy of prematurity.Covariates of intravenous paracetamol pharmacokinetics in adultsCurrent Therapeutic Research is Now Indexed on PubMed.Clinical pharmacology of paracetamol in neonates: a review.Paired measurement of urinary creatinine in neonates based on a Jaffe and an enzymatic IDMS-traceable assayQuantification of amikacin in bronchial epithelial lining fluid in neonates.Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonatesParacetamol pharmacokinetics and metabolism in young women.Open-Label Study To Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants Less than 12 Weeks in Chronological AgeDevelopmental changes rather than repeated administration drive paracetamol glucuronidation in neonates and infants.A bodyweight-dependent allometric exponent for scaling clearance across the human life-span.Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearanceProspective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical PracticeClinical pharmacokinetics of vancomycin in the neonate: a reviewAdverse drug reactions in neonates and infants: a population-tailored approach is needed.Effective analgesia after cesarean delivery needs pharmacokinetic input.Factors impacting unbound vancomycin concentrations in different patient populations.Catch-up growth in the first two years of life in Extremely Low Birth Weight (ELBW) infants is associated with lower body fat in young adolescence.Design and feasibility of "PREMATurity as predictor of children's Cardiovascular-renal Health" (PREMATCH): A pilot study.Clinical pharmacology in neonates and young infants: the benefit of a population-tailored approach.Commentary: Continuous infusion of vancomycin in neonates: to use or not to use remains the question.Population clinical pharmacology of children: modelling covariate effects.Population clinical pharmacology of children: general principles.Developmental pharmacokinetics of propylene glycol in preterm and term neonatesSimultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtrationTowards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling.Cystatin C in newborns: a promising renal biomarker in search for standardization and validation.
P50
Q26849339-87F7E5E3-735D-40F9-88C8-17F8D00A93C9Q27009662-AF3D68A5-A345-4462-91B4-B5BE6B905315Q27013749-EE0FFFD4-8B03-463D-8EEE-633525477E97Q27312881-1B529C7D-D753-416E-8E59-A8FF253E600DQ28078751-05C1574E-01C4-4854-8D23-9A81A9823D6FQ28194278-D526CC6D-A840-4627-BAC9-131D8D8DF202Q28211485-9F3F13A6-DA1B-4D04-BDF2-96102956C523Q30837825-A7EB9A63-3CD2-4B19-B1EE-9E9409D49136Q30990823-A54B14B2-D2A0-4B04-BA18-B8FA6571F43CQ33561249-939A9D16-759A-4560-9DDD-1C35E859176CQ33906451-378E4BDD-A74C-4C0E-8B05-37CB0EC2CD56Q33950874-2F586192-53E6-4929-8550-90AEC7A133E5Q33981087-498CE3B1-05E9-4B54-A258-1FE9C35B7514Q34066626-C7D8B223-5D64-4B65-80DB-F02CA7C08D40Q34193839-DC8E9D3C-74F3-405D-87EF-2E3634AFAA0CQ34484343-0FE0D7A9-4835-4AFD-87C1-C28E4C720E95Q35086268-09854588-0419-4FD2-A71D-CB58D39DB575Q35147367-72AC26B8-AC7D-4DA2-8ED6-DBC563DBAAE7Q35191478-4F575631-CC84-4AA6-9F4F-84CA672BB571Q35755665-90BAFE8E-D8F3-4901-AFC0-2820225A8B91Q35841159-5DBD8212-7190-4F25-A14F-E49B7339DC86Q35859870-C1CBE4C3-FD9D-4864-B390-1DFEDD20BA22Q35941220-978BB78B-0A56-41C4-8F08-05827D67898EQ35949142-81C2BB82-4796-4B60-A8B0-1C2BB5B7334DQ36024899-C15500D9-E493-410D-B0FA-DF143FECAE79Q36075844-0E275A3F-1CAF-4824-8024-075331AF93ECQ36104107-5ECFC64F-9B7B-417C-A562-FDB47F429E85Q36125509-79FC0F14-E26B-4DB9-9C31-BA82C7E374ACQ36133527-25B8FB32-7470-451B-A494-3DBB79B9DE88Q36158421-BF68BDE1-FC07-4EEA-AE36-D00A52B5C88DQ36302566-AC18F626-4A5A-4D08-9BC1-4E711A7D955FQ36357258-9FD85F5A-B593-4286-AB19-C13DBABEE3E0Q36452352-F4798B7B-84D7-4456-9242-A45048363C96Q36452357-4083BC01-3B47-4999-8BDD-7E24AAC8A14EQ36522932-2780B498-1FF8-4E32-9C38-B451091BE2F0Q36522936-8A626755-0037-47B1-B774-FD3723475C66Q36562475-1F095A62-372C-466E-A99B-4772828607B7Q36568925-0E7774E2-60D8-42F5-8007-268BD2172165Q36571794-EDBE74ED-F126-4159-ABBF-4478C8C34B79Q36590766-04B87183-6E48-48C6-9EB1-A8261D39A20A
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Karel Allegaert
@ast
Karel Allegaert
@en
Karel Allegaert
@es
Karel Allegaert
@nl
type
label
Karel Allegaert
@ast
Karel Allegaert
@en
Karel Allegaert
@es
Karel Allegaert
@nl
prefLabel
Karel Allegaert
@ast
Karel Allegaert
@en
Karel Allegaert
@es
Karel Allegaert
@nl
P106
P1153
7003304865
P2038
Karel_Allegaert
P31
P496
0000-0001-9921-5105